The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has
resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs …

Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …

Paclitaxel is a broad‐spectrum anticancer compound, which was derived mainly from a
medicinal plant, in particular, from the bark of the yew tree Taxus brevifolia Nutt. It is a …

Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …

The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Molecular targeted therapies are revolutionized therapeutics which interfere with specific
molecules to block cancer growth, progression, and metastasis. Many molecular targeted …

Significant advances in drug research and development are herein reviewed first to set the
background for a critical consideration of the economic sustainability of biologics and small …

Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the
treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 …